By vgreene, 3 April, 2020 Efficacy of Hydroxychloroquine in Patients With COVID-19: Results of a Randomized Clinical Trial
By vgreene, 3 April, 2020 Study considerations: not peer-reviewed; open-label; small sample size; mostly younger pts w/ mild dz; excl severe and critically ill pts; limited f/u for safety outcomes
By vgreene, 3 April, 2020 HCQ-treated pts had shorter duration of cough (2.0 days vs 3.1 days) and fever (2.2 days vs 3.2 days), and higher rates of pneumonia improvement (80.6% vs 54.8%); 4 pts in placebo arm progressed to severe dz; 2 pts in HCQ arm developed mild ADRs
By vgreene, 3 April, 2020 RCT; 62 hospitalized pts (mean age, 45y) w/ mild dz (SAO2 >93%) due to confirmed COVID-19 randomized to HCQ 200 mg bid x5 days or placebo, plus SOC
By vgreene, 2 April, 2020 Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: A Randomized Clinical Trial, NCT04306393
By vgreene, 2 April, 2020 An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19, ClinicalTrials.gov
By vgreene, 2 April, 2020 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia, NCT04320615